PD‐L1 and PD‐1 expression in pediatric post‐transplant Burkitt lymphoma and other monomorphic post‐transplant lymphoproliferative disorders
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30674 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Ashley V Geerlinks und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology/Oncology, Children's Hospital, Schulich School of Medicine, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, B7-H1 Antigen, Burkitt Lymphoma, Lymphoproliferative Disorders. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Post‐transplant lymphoproliferative disorders (PTLD) develop as a consequence of immune suppression. Programmed death protein 1 (PD‐1), a regulator of host immune activation, binds to programmed death‐ligand 1 (PD‐L1) to suppress the T‐cell immune response. PD‐1/PD‐L1 pathway may play a role in PTLD. The objective was to describe intratumoral expression of PD‐L1 and PD‐1 in pediatric monomorphic PTLD, and assess if density of these cells is associated with progression‐free survival (PFS) and overall survival (OS). Procedure Clinical variables and outcome data were collected on B‐cell monomorphic PTLD treated in Toronto, Canada between 2000 and 2017. Diagnostic area from tumor tissue was identified to count CD3‐positive or PD‐1‐positive cells and CD3‐negative lymphoma B cells or PD‐L1‐positive cells. CD3 + , PD‐1 + , and PD‐L1 + cell densities were compared between cases of PTLD. OS and PFS were analyzed.
Results
We identified 25 cases of B‐cell monomorphic PTLD; majority Burkitt lymphoma (32%) and diffuse large B‐cell lymphoma (56%). All cases had CD3 + cells infiltrating the tumor, and median percentage of CD3 + cells was 14% (interquartile range: 6.2%–25%). Twelve cases (48%) had PD‐1 + cell infiltrating (range: 1%–83%) and 13 cases (52%) had no PD‐1 + cells infiltrating. Sixteen cases (64%) had PD‐L1 + cells present; however, there was no PD‐L1 expression on any Burkitt lymphoma tissue. When comparing PD‐1 and PD‐L1 expression, there was no difference in OS or PFS.
Conclusion
Intratumoral presence of PD‐1 + and PD‐L1 + cells varied in pediatric patients with monomorphic PTLD; however, no relationship to OS and PFS was identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Hematology/Oncology, Children's Hospital, Schulich School of Medicine, Western University, London, Ontario, Canada.
- Division of Infectious Diseases, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
- Division of Pathology, Department of Pediatric Laboratory Medicine, Hospital for Sick Children, Toronto, Ontario, Canada.
- Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
ORCID-Profile: Angela Punnett
Zitieren
APA
Geerlinks, A. V., Allen, U., Ngan, B. Y., & Punnett, A. (2023). PD‐L1 and PD‐1 expression in pediatric post‐transplant Burkitt lymphoma and other monomorphic post‐transplant lymphoproliferative disorders. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30674
Vancouver
Geerlinks AV, Allen U, Ngan BY, Punnett A. PD‐L1 and PD‐1 expression in pediatric post‐transplant Burkitt lymphoma and other monomorphic post‐transplant lymphoproliferative disorders. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30674
BibTeX
@article{Geerlinks2023,
author = {Geerlinks, Ashley V and Allen, Upton and Ngan, Bo-Yee and Punnett, Angela},
title = {PD‐L1 and PD‐1 expression in pediatric post‐transplant Burkitt lymphoma and other monomorphic post‐transplant lymphoproliferative disorders},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30674}
}
EUVIMED